Skip to content

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    0 and up

Participation Criteria

Inclusion Criteria:

* Diagnosis of BPDCN
* Signed informed consent form for prospective patients

Exclusion Criteria:

-

Study Location

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contact Study Team

Primary Contact

Carolyn Owen, MD

[email protected]
Children's Hospital of Eastern Ontario, University of Ottawa
Children's Hospital of Eastern Ontario, University of Ottawa
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Consolato Sergi, MD, PhD

[email protected]
Study Sponsored By
Immune Oncology Research Institute
Participants Required
More Information
Study ID: NCT05430971